Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma

Official title

A Randomized, Double-Blind, Chronic-Dosing (14 Days), 5-Period, 7-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multicenter, Dose-ranging Study to Assess the Efficacy and Safety of PT001 Relative to Placebo Metered Dose Inhaler and Open-Label Serevent® Diskus® in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma

Study identification

NCT ID

NCT02433834

Recruitment status

Completed

Study type

Interventional

Phase

Phase 2

Lead sponsor

Pearl Therapeutics, Inc.

Industry

Enrollment

248 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years to 70 Years

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

May 26, 2015

Primary completion

Mar 25, 2016

Completion

Mar 25, 2016

Last update posted

Jul 1, 2017

2015 – 2016

United States locations

U.S. sites

43

U.S. states

15

U.S. cities

39

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.